EXCLUSIVE: Adial Pharma Announces Key Patent To Combine Genetic Diagnostic With Lead Drug For Alcohol Addiction
Adial Pharmaceuticals Inc (NASDAQ: ADIL) has been awarded a key patent combining the use of the company's proprietary genetic diagnostic to detect select genotypes for genetically targeted treatment of alcohol use disorder (AUD) and opioid use disorder (OUD) with the company's lead investigational product AD04.
AD04 is a genetically targeted, serotonin-3 receptor antagonist therapeutic agent for Alcohol Use Disorder in heavy drinking patients.
"This patent marks another important milestone in our pursuit to provide tailored, more effective treatments for individuals grappling with AUD and OUD," stated Cary Claiborne, CEO of Adial Pharmaceuticals.
In July, Adial Pharmaceuticals provided a summary of feedback received following recent meetings with both U.S. and EU regulators and an update on the company's current clinical development plan based on guidance received.
The authorities acknowledged that the results from the Phase 2 and Phase 3 post hoc analysis against the U.S. endpoint of PNHDD demonstrated the statistical significance of responder analysis of specific genotypes as helpful information for planning future studies of AD04.
Price Action: ADIL shares are up 3.06% at $2.86 on the last check Thursday.
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article EXCLUSIVE: Adial Pharma Announces Key Patent To Combine Genetic Diagnostic With Lead Drug For Alcohol Addiction originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
